ESSA Pharma Inc. Class Action: The Gross Law Firm Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Allegations - The complaint alleges that during the class period from December 12, 2023, to October 31, 2024, defendants made materially false and misleading statements about masofaniten's efficacy [1]. - It is claimed that masofaniten in combination with enzalutamide did not demonstrate a clear efficacy benefit over enzalutamide alone [1]. - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, contradicting the defendants' public statements [1]. - Defendants allegedly overstated masofaniten's clinical, regulatory, and commercial prospects, leading to inflated stock prices [1]. Next Steps for Shareholders - Shareholders who purchased shares of EPIX during the specified timeframe are encouraged to register for the class action by March 25, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through portfolio monitoring software throughout the case lifecycle [2]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].